Goldman Sachs Suggests Buying Calls on Pfizer

Goldman Sachs is out with a research note this morning, where it suggests that traders buy calls on Pfizer PFE ahead of the August 28th data release. Goldman's analyst expects Apixaban (Eliquis, an anticoagulant) annual sales to reach $3-$4 bn. Given the top-line release for this drug met the best-case of superiority on efficacy and bleeding, her conversations with cardiology thought leaders suggest that Eliquis is likely to be best-in-class and achieve a leading market share. With PFE shares down 14% since top-line release of Apixaban, versus 5% decline of peers, the analyst believes that PFE shares do not reflect the value of Eliquis, or other drugs in the pipeline. The analysts suggest buying the September $18 call for $0.80. Pfizer Inc. is a research-based, global biopharmaceutical company. The company operates in two segments: Biopharmaceutical and Diversified. Biopharmaceutical includes the Primary Care, Specialty Care, Established Products, Emerging Markets and Oncology customer-focused units, which includes products that prevent and treat cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, respiratory diseases, urogenital conditions, cancer, eye disease and endocrine disorders, among others.